Preclinical evaluation of 213Bi-/225Ac-labeled low-molecular-weight compounds for radiopharmaceutical therapy of prostate cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Preclinical evaluation of 213Bi-/225Ac-labeled low-molecular-weight compounds for radiopharmaceutical therapy of prostate cancer

Published:2020-11-27 Issue: Volume: Page:jnumed.120.256388
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Ray Sangeeta,Lisok Ala,Minn IL,Josefsson Anders,Kumar Vivek,Brummet Mary,Boinapally Srikanth,Brayton Cory,Mease Ronnie C,Sgouros George,Hobbs Robert F,Pomper Martin G.

Publisher

Society of Nuclear Medicine

Subject

Radiology Nuclear Medicine and imaging

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Performance of PSMA-targeted radiotheranostics in an experimental model of renal cell carcinoma;Frontiers in Oncology;2024-09-10

2. A third generation PSMA-targeted agent [211At]YF2: Synthesis and in vivo evaluation;Nuclear Medicine and Biology;2024-07

3. Recent advances in the development of 225Ac- and 211At-labeled radioligands for radiotheranostics;Analytical Sciences;2024-04-02

4. Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives;EJNMMI Radiopharmacy and Chemistry;2024-02-06

5. Actinium-225 targeted alpha particle therapy for prostate cancer;Theranostics;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP